Nigel Brooksby joins Prism Ideas
pharmafile | September 2, 2010 | Appointment | Medical Communications, Research and Development | Prism Ideas, appointment, medical communications, research and development
Former Sanofi-Aventis UK chairman and managing director Nigel Brooksby has joined Cheshire, UK-based Prism Ideas as non-executive chairman.
The medical communications and drug development consultancy said Nigel’s appointment was a key part of its growth strategy.
Commenting on his new role Nigel said: “Prism Ideas is at a very exciting time in its development with a strong reputation for delivering scientific excellence and innovation. I am delighted to be joining the company’s leadership team and am looking forward to the opportunity to help build on its success.”
He has more than 35 years’ experience in the life sciences industry, most recently heading up Sanofi-Aventis UK and leading the UK’s Association of the British Pharmaceutical Industry (ABPI) for two years.
Earlier this year Nigel was made chairman of the board of trustees of the Primary Care Cardiovascular Society and has recently been invited to join the advisory board of the Imperial Clinical Trials Unit at Imperial College London.
Prism’s chief executive Dr James Sawyer said: “Nigel’s incredible track-record in the pharmaceutical industry makes him a great addition to our management team. His global knowledge of the industry will be an invaluable asset as we establish our new offices overseas and develop broader services for our clients.
“By becoming our chairman Nigel will offer Prism Ideas unrivaled advice and support to continue to ensure that we maintain the progress and direction that has made the company a success.”
Related Content
Men’s health – a new report from the Department of Health and Social Care
The UK Department of Health and Social Care has published a new report entitled Men’s …
PlasmidFactory founder Dr. Martin Schleef honoured with the NRW Innovation Award 2025
The founder and long-standing CEO of PlasmidFactory, Dr. Martin Schleef, was honoured in Düsseldorf with …
AAX Biotech announces collaboration for cardiovascular antibody therapy
Swedish biotech firm AAX Biotech has entered a new collaboration focused on the development of …
